Compare Infosys Limited (INFY) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Tango Therapeutics Inc. — how do they compare? Infosys Limited trades at $11.77 (market cap $44.92B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Infosys Limited is far larger — about 12× Tango Therapeutics Inc.'s market cap, and Infosys Limited pays a 4.59% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Infosys Limited for 26 Days and Tango Therapeutics Inc. for 0 Days on average.
| INFY | TNGX | |
|---|---|---|
Market Cap | $44.92B | $3.75B |
Volume | 25,564,570 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $20.22 | $32.90 |
52-Week Low | $10.49 | $7.50 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $42.66B | $2.77B |
Dividend Yield | 4.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $11.40, up 5.26% today, with a bullish technical signal driven by oversold RSI conditions. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.23 exceeding expectations. Revenue for 2025 was $19.28B, with a net income margin of 16.37%. Recent news highlights strategic AI collaborations with Columbia University and ABN Amro, positioning the firm for innovation-driven growth.
The outlook is cautiously optimistic, supported by solid profitability and strategic partnerships, but tempered by a mixed analyst consensus and potential net cash flow decline in 2026. Key risks include competitive pressures in IT services and macroeconomic sensitivity. The consensus price target of $11.48 suggests limited near-term upside from current levels.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
